Pirche AG
Pirche is a global technology leader in the application of AI to molecular medicine. Its back end epitope matching technology is redefining compatibility risk assessment as a prerequisite for foreign tissue or allogeneic cells to be accepted by the patient immune system. Pirche‘s front end product is a first and only-in-class proprietary digital diagnostic platform that enables physicians and drug developers to make informed decisions with unprecedented precision. Over 850 leading clinics worldwide are networked with Pirche. Based on its fundamental IP, Pirche is partnering with industry leaders to make a profound impact on the future of healthcare in transplant medicine, autoimmunity and oncology.
Field of Activity |
In transplant medicine, donor-recipient risk assessment to improve organ survival and management of long-term immunosuppression, and in allogeneic cell therapy, design and ‘off-the-shelf’ selection utilizing immune risk profi ling in autoimmunity and oncology |
Ownership structure and financing |
German Stock Corporation (Aktiengesellschaft); A-series upcoming; break-even within 24 months expected |
Partners |
Werfen, Thermo Fisher Scientifi c, Immucor; 850+ clinics and transplant centers globally
|
Technology | The epitope matching technology combines genetic typing with realtime AI-supported immunological simulations of protein interactions. Protected by 25 gratec patents and a proven medical evidence with 70+ peer reviewed publications on more than 200,000 patient cases.
|
Products/services | Fully digital diagnostic platform and prediction pipeline based on standard lab data for donor-recipient risk assessment, management of immunosuppression and support of allogeneic cell therapy design and allocation. |
Unique selling point |
Pirche‘s patented epitope matching technology transforms transplant medicine and cell therapies driven by exclusive AI algorithms, solid science, and forward-thinking industry partners. |
Membership in networks/associations | ASHI – American Society for Histocompatibility and Immunogenetics;
TTC – Transplant Therapeutics Consortium; Bio Deutschland |
Date of Incorporation/Number of Employees | 08/2015/15 employees |
|
|
contact: |
|
Adresse | US: 266 Main Street, Medfield, MA 02052
EU: Nördliche Münchner Straße 27a, 82031 Grünwald, Germany |
Telefon | Medfield: +1 617 233 7699
Grünwald: +49 89 9090 153 914 |
Thomas Klein is your contact for spoken communication: thomas.klein@pirche.com | |
Web-Adresse | https://pirche.com |
Social Media |
- „Das Problem des ‚Undruggable‘ war bisher ein Problem des ‚Invisible‘, das wir gelöst haben.“
- Out now! Special „Corporate Finance Recht 2024“
- Molecular Health und Integrated DNA Technologies vereinbaren kommerzielle Partnerschaft
- 23 Millionen Euro für Smart Reporting
- Can biopharma’s drug-focused R&D strategy remain profitable?
- Vorschau auf die analytica 2024
- Wie künstliche Intelligenz die Gesundheitsindustrie verändert
- Hey, it’s a Match!
- Navigating the AI Revolution - A Venture Capitalist‘s Journey in Transforming Healthcare
- Heading the digital transformation in the life sciences industry
- How to achieve investment readiness in the food industry?
- The potential of AI in drug discovery
- W&I-Policen zunehmend für kleinere Deals zugänglich
- Was Künstliche Intelligenz im M&A-Geschäft bringt
- BioNTech schließt Übernahme von InstaDeep ab
- KI für Gewebeproben: AIgnostics erhält Seed-Finanzierung
- Münchener inveox erhält weiteres Investment
- Predicting clinical trial success and improving R&D
- Molecular Health lizenziert prädiktives analytisches Produkt MH Predict an DATEN CAPITAL
- EVOTEC beteiligt sich an Finanzierungsrunde für AI-Wirkstoffforschungsunternehmen Exscientia